SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10645	Companies
226425	Keywords
154888	Articles
119845	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 10/17/2025 at 13:00, 8 months 9 days ago

Communiqué de presse : Sanofi fournit une mise à jour de l’examen réglementaire du Rezurock dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
Sanofi demande un réexamen après un avis négatif du CHMP pour le Rezurock dans le traitement de la maladie chronique du greffon contre l’hôte en Europe

Sanofi CHMP Rezurock Maladie Chronique Greffon
PRESS RELEASE

published on 10/17/2025 at 13:00, 8 months 9 days ago

Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi announces negative CHMP opinion on Rezurock for chronic graft-vs-host disease in the EU but plans to seek re-examination. Rezurock has shown efficacy in clinical studies

EU Sanofi CHMP Rezurock CGVHD
BRIEF

published on 10/08/2025 at 07:05, 8 months 18 days ago

AlphaMedixTM: Positive Phase 2 Results for the Treatment of GEP-NETs

Clinical Trial Phase 2 Innovative Therapy AlphaMedixTM TNE-GEP
BRIEF

published on 10/08/2025 at 07:05, 8 months 18 days ago

AlphaMedixTM : des résultats positifs en phase 2 pour le traitement des TNE-GEP

Essai Clinique Phase 2 Thérapie Innovante AlphaMedixTM TNE-GEP
PRESS RELEASE

published on 10/08/2025 at 07:00, 8 months 18 days ago

Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints
AlphaMedixTM (212Pb-DOTAMTATE) satisfait les critères d'évaluation principaux d'efficacité dans l'essai de phase 2 pour les tumeurs neuroendocrines gastro-entéro-pancréatiques. Résultats prometteurs d'alphathérapie ciblée au plomb-212

Essai De Phase 2 Tumeurs Neuroendocrines AlphaMedixTM 212Pb-DOTAMTATE Alphathérapie Ciblée
BRIEF

published on 09/24/2025 at 07:10, 9 months 2 days ago

Sanofi investit 625 millions de dollars pour booster Sanofi Ventures

Investissement Innovation Santé Numérique Sanofi Biotechnologies
BRIEF

published on 09/24/2025 at 07:10, 9 months 2 days ago

Sanofi invests $625 million to boost Sanofi Ventures

Innovation Digital Health Investment Sanofi Biotechnologies
BRIEF

published on 09/24/2025 at 07:05, 9 months 2 days ago

Sanofi publie son aide-mémoire pour le troisième trimestre 2025

Relations Avec Les Investisseurs Sanofi Annonce Des Résultats Modélisation Financière T3 2025
PRESS RELEASE

published on 09/24/2025 at 07:05, 9 months 2 days ago

Communiqué de presse : Sanofi engage 625 millions de dollars supplémentaires dans Sanofi Ventures, afin d’accélérer ses investissements dans les biotechnologies et l’innovation en matière de santé numérique
Sanofi investit 625 millions de dollars supplémentaires dans Sanofi Ventures pour accélérer les investissements en biotechnologies et innovation numérique dans la santé

Investissement Innovation Santé Numérique Sanofi Biotechnologies
BRIEF

published on 09/24/2025 at 07:05, 9 months 2 days ago

Sanofi Releases Q3 2025 Aide Mémoire

Investor Relations Sanofi Financial Modeling Results Announcement Q3 2025

Accesswire

Published on 06/26/2026 at 13:00, 26 minutes ago

Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 41 minutes ago

Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 01:40, 11 hours 46 minutes ago

UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 13 hours 56 minutes ago

Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 14 hours 56 minutes ago

Fountain Asset Corp. Provides Corporate Update

View all ACCESSWIRE

EQS Group

Published on 06/26/2026 at 13:00, 26 minutes ago

Schweizer Electronic and Ascent Circuits Plan Strategic Indo-German PCB Cooperation
Published on 06/26/2026 at 12:30, 56 minutes ago

Multi Units Luxembourg: NOTICE TO THE SHAREHOLDERS
Published on 06/26/2026 at 12:18, 1 hour 8 minutes ago

EQS-Adhoc: EPH Group AG: EPH Group AG Extends Subscription Period for New EPH Shares Until 31 July 2026
Published on 06/26/2026 at 11:30, 1 hour 56 minutes ago

Amundi Index Solutions: NOTICE TO SHAREHOLDERS
Published on 06/26/2026 at 11:14, 2 hours 11 minutes ago

EQS-Adhoc: Evonik Industries AG: Current financial and forecast data for the second quarter of 2026 and adjustment of the outlook for the financial year 2026

Les Echos

Published on 06/26/2026 at 12:16, 1 hour 10 minutes ago

Rapport semestriel SIEHM au 30 avril 2026
Published on 06/26/2026 at 07:00, 6 hours 26 minutes ago

Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 6 hours 26 minutes ago

Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 18 hours 41 minutes ago

Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 18 hours 56 minutes ago

Avis financier semestriel SIEHM au 30 avril 2026

View all LES ECHOS COMFI WIRE